Matritech, Inc. (AMEX: MZT) Q4/06 Review Issued by Scimitar Equity Research, Inc.
07 Février 2007 - 3:32PM
PR Newswire (US)
BOSTON, Feb. 7 /PRNewswire/ -- Scimitar Equity Research, Inc.
issues a review on Matritech, Inc. (AMEX:MZT) entitled
""Encouraging Q4 and FY06 Results, Financing, AMEX Compliance and
FY07 Guidance". The analyst research review is available on
Scimitar's website: http://www.scimitarequity.com/. Matritech, Inc.
is using its patented proteomics technology to develop diagnostics
for the detection of a variety of cancers. MZT's first two
products, the NMP22(R) Test Kit and NMP22(R) BladderChek(R) Test,
have been FDA approved for the monitoring and diagnosis of bladder
cancer. The NMP22 BladderChek Test is based on Matritech's
proprietary nuclear matrix protein (NMP) technology, which
correlates levels of NMP's in body fluids to the presence of
cancer. Beginning with a patent portfolio licensed exclusively from
the Massachusetts Institute of Technology (MIT), Matritech's patent
portfolio has grown to 14 other U.S. patents. In addition to the
NMP22 protein marker utilized in the NMP22 Test Kit and NMP22
BladderChek Test, MZT has discovered other proteins associated with
cervical, breast, prostate, and colon cancer. MZT's goal is to
utilize protein markers to develop, through its own research staff
and through strategic alliances, clinical applications to detect
cancer. More information about Matritech is available at:
http://www.matritech.com/ Scimitar Equity Research, Inc. provides
sponsored equity research of the healthcare industry for the
institutional and investment communities. We certify that all the
views expressed in this review, accurately reflect our personal
views about Matritech, Inc (AMEX:MZT) and its or their securities.
No part of our compensation was, is, or will be, directly or
indirectly, related to the specific recommendations or views
contained in this review and we will not have any investment
banking relationships or personal investment in any sponsored
company. Investors are advised that this analysis and review is
issued solely for informational purposes and is not to be construed
as an offer to sell or the solicitation of an offer to buy.
Scimitar was paid for preparing this review. This analysis and
review does not have regard to the specific investment objectives,
financial situation and the information contained herein is based
on sources that we believe to be reliable but is not guaranteed by
us as being accurate. Any opinions expressed are statements of our
own judgment as of the date of publication and are subject to
change without notice. Please read all our important disclosures.
CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director
of Research phone: (617) 559-1080 fax: (617) 559-1083 e-mail:
DATASOURCE: Scimitar Equity Research, Inc. CONTACT: Henry W.
McCusker, Director of Research of Scimitar Equity Research, Inc.,
+1-617-559-1080, or fax, +1-617-559-1083, or Web site:
http://www.scimitarequity.com/ http://www.matritech.com/
Copyright
Matritech (AMEX:MZT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Matritech (AMEX:MZT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Matritech, (American Stock Exchange): 0 recent articles
Plus d'articles sur Matritech